InvestorsHub Logo
Followers 12
Posts 3886
Boards Moderated 0
Alias Born 04/30/2004

Re: None

Thursday, 11/29/2018 3:06:45 PM

Thursday, November 29, 2018 3:06:45 PM

Post# of 1722
San Diego, CA-based TrovaGene Inc. (NASDAQ:TROV) , a molecular diagnostic company, recently announced encouraging data pertaining to its Precision Cancer Monitoring (PCM) technology for both urine and plasma EGFR mutation testing. Notably, the results demonstrated greater detection sensitivity for PCM compared to tissue testing alone. The data will be presented in Vienna, Austria at the 17th World Conference on Lung Cancer.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CRDF News